Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease

doi:10.16352/j.issn.1001-6325.2023.10.1594

Abstract

CLC Number:

R392

HUANG Lichenlu, ZHANG Jiarui, ZHENG Yongqin, HE Jundong. Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease[J]. Basic & Clinical Medicine, 2023, 43(10): 1594-1598.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.10.1594

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I10/1594

References

[1]史冬雪,原佳琪,丁宝锋等. 非酒精性脂肪肝病模型小鼠的肝脏病理变化及肝细胞获取方法[J]. 基础医学与临床, 2022, 42:890-895
[2]Donne R,Saroul-Ainama M,Cordier P,et al. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD[J]. Dev Cell, 2022, 57:1728-1741.e6.
[3]Aragón-Herrera A,Otero-Santiago M,Anido-Varela L,et al. The treatment with the SGLT2 inhibitor empagliflozin modifies the hepatic metabolome of male zucker diabetic fatty rats towards a protective profile[J]. Front Pharmacol, 2022, 13:827033.doi:827010.823389/fphar.822022.827033.
[4]Wang S,Sheng F,Zou L,et al. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism[J]. J Adv Res, 2021, 34:109-122.
[5]Li L,Li Q,Huang W,et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway[J]. Front Pharmacol,2021, 12:589273.doi:589210.583389/fphar.582021.589273.
[6]Latif M,Schmidt G,Mercan S,et al. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression[J]. Gut, 2022, 71:2561-2573.
[7]Murakami K,Sasaki Y,Asahiyama M,et al. Selective PPARα modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor Tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis[J]. Cells, 2022, 11:720.doi:710.3390/cells11040720.
[8]Nasiri-Ansari N,Nikolopoulou C,Papoutsi K,et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-/-) mice by activating autophagy and reducing ER stress and apoptosis[J]. Int J Mol Sci, 2021, 22:818.doi:810.3390/ijms22020818.
[9]Zhu W,Sahar N,Javaid H,et al. Exercise-induced irisin decreases inflammation and improves NAFLD by competitive binding with MD2[J]. Cells, 2021, 10:3306.doi:3310.3390/cells10123306.
[10]Xu Z,Hu W,Wang B,et al. Canagliflozin ameliorates nonalcoholic fatty liver disease by regulating lipid metabolism and inhibiting inflammation through induction of autophagy[J]. Yonsei Med J, 2022, 63:619-631.
[11]Ozutsumi T,Namisaki T,Shimozato N,et al. Combined treatment with sodium-glucose cotransporter-2 inhibitor (Canagliflozin) and dipeptidyl peptidase-4 inhibitor (Teneligliptin) alleviates NASH progression in a non-diabetic rat model of steatohepatitis[J]. Int J Mol Sci, 2020, 21:2164.doi:2110.3390/ijms21062164.
[12]Morishita A,Tadokoro T,Fujihara S,et al. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model[J]. PLoS One, 2022, 17:e0261310.doi:0261310.0261371/journal.pone.0261310.
[13]Elmahdy MK,Helal MG,Ebrahim TM. Potential anti-inflammatory effect of dapagliflozin in HCHF diet-induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver[J]. Int Immunopharmacol, 2020, 86:106730.doi: 10.1016/j.intimp.2020.106730.
[14]Hüttl M,Markova I,Miklankova D,et al. In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia[J]. Int J Mol Sci, 2021, 22:11513.doi:11510.13390/ijms222111513.
[15]Perakakis N,Chrysafi P,Feigh M,et al. Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH[J]. Int J Mol Sci, 2021, 22:6332.doi:6310.3390/ijms22126332.
[16]Meng Z,Liu X,Li T,et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway[J]. Int Immunopharmacol, 2021, 94:107492.
[17]Hupa-Breier K,Dywicki J,Hartleben B,et al. Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH[J]. Biomedicines, 2021, 9:353.doi:310.3390/biomedicines9040353.
[18]Cai B,Dongiovanni P,Corey K,et al. Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis[J]. Cell Metab, 2020, 31:406-421.e407.
[19]Yoshioka N,Tanaka M,Ochi K,et al. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model[J]. Biomed Pharmacother, 2021, 140:111738.doi: 10.1016/j.biopha.2021.111738.
[20]Kimura A,Kamimura K,Ohkoshi-Yamada M,et al. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model[J]. Biochem Biophys Res Commun,2022, 596:76-82.
[21]Jojima T,Wakamatsu S,Kase M,et al. The SGLT2 inhibitor Canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma[J]. Int J Mol Sci, 2019, 20:5237.doi:5210.3390/ijms20205237.